This study by Monash Alfred Psychiatry Research Centre (MAPrc) is being conducted in order to determine if two different doses of EVP-6124 improve mental function and are safe in people who have schizophrenia and are taking another medication for their illness. Contact: Mr Daniel Grice ph (03) 9076 6581 Email participate.maprc@monash.edu Website link: http://www.maprc.org.au/psychopharmacology.
Participants sought: Are you interested in trying a new non-medication treatment for Depression?
Participants sought: Do you have Type 2 diabetes and sit for large portions of the day?
Scientists at the Physical Activity & Behavioural Epidemiology lab, Baker IDI Heart and Diabetes Institute recently discovered that breaking up prolonged sitting has important beneficial effects on glycaemic control in older adults. We now aim to further investigate this phenomenon in those with type 2 diabetes, who are likely to derive the greatest benefits. This research may ultimately lead to practical and feasible treatment and management strategies in those with type 2 diabetes.
The purpose of this study is to investigate the use of the medication Ondansetron as an adjunctive or add-on therapy to existing anti-psychotic medication in the treatment of schizophrenia symptoms. Ondansetron is a well established medication which is approved in Australia for the treatment of drug-induced nausea and vomiting. However, various case studies and clinical studies have shown Ondansetron to also be effective in the treatment of symptoms associated with persistent schizophrenia.
Volunteers are required to investigate the role of wheat gluten in causing gastrointestinal symptoms and changes in mental health in people who do not have coeliac disease.
We are looking for participants who have found that following a gluten-free diet has relieved their gut symptoms
Participants sought: Investigating Ondansetron for chronic residual schizophrenia
The purpose of this study is to investigate the use of the medication Ondansetron as an adjunctive or add-on therapy to existing anti-psychotic medication in the treatment of schizophrenia symptoms. Ondansetron is a well established medication which is approved in Australia for the treatment of drug-induced nausea and vomiting. However, various case studies and clinical studies have shown Ondansetron to also be effective in the treatment of symptoms associated with persistent schizophrenia.
Participants sought: The role of wheat gluten in causing gastrointestinal symptoms and changes to mental health
We are looking for participants who have found that following a gluten-free diet has relieved their gut symptoms
